Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | EDNRA | P25101 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152522 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL1094138 | 0.83 | POLB (0.55) | SMN1; SMN2POLBALDH1A1KDM4ELMNA | |
| SCHEMBL28409808 | 0.83 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL19332236 | 0.80 | KDM4E (0.70) | POLBALDH1A1KDM4EMAPT | |
| SCHEMBL6292016 | 0.79 | SLC40A1 (0.55) | SMN1; SMN2EDNRA | |
| SCHEMBL15215659 | 0.79 | POLB (0.72) | SMN1; SMN2POLBALDH1A1KDM4EMAPT | |
| SCHEMBL19332648 | 0.78 | KDM4E (0.47) | SMN1; SMN2POLBALDH1A1KDM4ELMNA | |
| SCHEMBL31748788 | 0.78 | ALDH1A1 (0.82) | POLBALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL3486122 | 0.78 | ALDH1A1 (0.82) | POLBALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL18843940 | 0.77 | SCN9A (0.54) | SMN1; SMN2POLBALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624041-B2 | Heterocyclic compound and use thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-20240317755-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| CN-114907408-B | Heterocyclic compound, intermediate thereof, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4289846-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289846-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4174069-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| EP-4174069-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| US-20170120231-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-3154689-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
| EP-2945623-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou yunxuan yiyaokeji youxiangongsi (Su Zhou Yuan Pharm) (CN) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014113191-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | ZHANG XIAOHU (CN) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014113191-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | ZHANG XIAOHU (CN) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624041-B2 | Heterocyclic compound and use thereof | TRPC1, TRPC5, TRPC3 | SMN1; SMN2 2401/4885POLB 3847/4885ALDH1A1 1028/4885 |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | SMN1; SMN2 2439/4885POLB 3113/4885ALDH1A1 596/4885 |
| US-20170120231-A1 | COMPLEXES | AP3M1, CYCS, AP1M1 | SMN1; SMN2 2773/4885POLB 247/4885ALDH1A1 1792/4885 |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TRPC5, TRPC1, GOT1 | SMN1; SMN2 4015/4885POLB 3532/4885ALDH1A1 2155/4885 |
| US-20240317755-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4A11, CYP4F11, CYP51A1 | SMN1; SMN2 3095/4885POLB 3759/4885ALDH1A1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.